MMCB has successfully completed in vitro (in vitro) laboratory tests of a range of new gene therapy drugs for the treatment of hemophilia A and B. Now the company's specialists have launched a testing phase on mice in order to determine the minimum effective dose of the drug. The hemophilia therapy market remains one of the largest segments of orphan disease...

Collection of applications for participation in the placement of 3,370,080 additional ordinary shares of the MMTS will take place from June 15 to June 18, inclusive. Price guideline will be announced before the start of the application process. The final placement price will be disclosed no later than June 19, 2026. Purpose of the additional issue is to ensu...

Shareholders of IMCB approved dividends for 2025 in the amount of ₽2.8 per ordinary share. The last day of purchase of securities to receive dividends is June 11, 2026. Dividend yield may amount to 2.29%.

MMCB's RAS net profit for 3 months of 2026 was ₽39.9 million, which is 9.9% lower than ₽44.3 million in the previous year. Revenue increased by 7.8% to ₽97 million, compared to ₽90 million a year earlier.